3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Multiple Myeloma
68
Recurrence
7
Smoldering Multiple Myeloma
4
Neoplasms
4
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Plasmablastic Lymphoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Immunoglobulin Light-chain Amyloidosis
2
Plasmacytoma
1
Paraproteinemias
1
Neoplasms, Plasma Cell
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Plasma Cell
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
palbociclib
1
nilotinib
1
isatuximab
1
avelumab
1
atezolizumab
1
acalabrutinib
1
Whole-Body Irradiation
1
Trastuzumab
1
Sirolimus
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
daratumumab
×
90 days
×
Clear all
No trials found.